Brief: Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025
22/05/2025 13:39
May 22 (Reuters) - Windtree Therapeutics Inc WINT.O: WINDTREE THERAPEUTICS ANNOUNCES ISTAROXIME CARDIOGENIC SHOCK SCAI STAGE C PHASE 2 STUDY PLANNED INTERIM ANALYSIS RESULTS TARGETED FOR JULY 2025 Source text: ID:nGNX6b2RtW Further company coverage: WINT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Windtree Therapeutics
See all newsBrief: Windtree Therapeutics Announces It Has Signed A Letter Of Intent To Acquire Commloan
Brief: Windtree Therapeutics Announces It May Receive License Agreement Payments From Its Licensee For Renewed Acute Pulmonary Development By The Licensee
Brief: Windtree Therapeutics Stockholders Approve Key Proposals For Revenue And Profit Generation At The Special Stockholder Meeting
Brief: Windtree Therapeutics Terminates Seismic-C Clinical Study At 20 Enrollments - SEC Filing
Brief: Windtree Therapeutics Inc - Announces Interim Analysis Of Istaroxime Phase 2 Study